Our Investment in Manas AI
Summary
With its ability to analyze vast datasets, predict molecular interactions, and streamline testing, applied AI can exponentially reduce the time, cost, and failure rates traditionally associated with bringing new therapeutics to market. In line with our health assurance thesis, we must harness this technological breakthrough to deliver life-saving therapies to patients who lack access to effective treatments.Were proud to welcome Manas AIs co-founders to the GC Famiglia: Dr. Siddhartha Mukherjee, a globally-recognized oncologist, researcher, author of critically acclaimed books like The Emperor of All Maladies: A Biography of Cancer, and Pulitzer Prize winner, along with Reid Hoffman, prolific entrepreneur, best known as the co-founder and executive chairman of LinkedIn, as well as a storied investor. In partnership with Microsoft, Manas AI utilizes powerful cloud computing to perform molecular dockinga technique that simulates how a drug interacts with its target protein, helping researchers predict how effectively the drug will bind and function100 times faster than traditional methods. The companys Project Cosmos focuses on elucidating the core principles of drug binding, speeding up the discovery of new chemical compounds.Imagine a world where effective treatments for lymphoma, triple-negative breast cancer, and rare diseases are within reach. We are honored to partner with the team to push the boundaries of drug discovery and make AI-enabled medical breakthroughs possible.